Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease

医学 赛马鲁肽 肾脏疾病 糖尿病 内科学 肾 2型糖尿病 疾病 胃肠病学 内分泌学 慢性病 泌尿科
作者
Katherine R. Tuttle,George L. Bakris,Florian M.M. Baeres,Casper N. Bang,Willem A. Bax,Nicolas Belmar,Derrick Musinga,David Z.I. Cherney,Gil Chernin,Soo Kun Lim,Johannes F.E. Mann,Vlado Perkovic,Richard E. Pratley,Paul M. Ridker,Peter R Rossing,Roland Schmieder,Минара Шамхаловна Шамхалова,L. Sreenivasamurthy,Kenneth W. Mahaffey
出处
期刊:Journal of the American College of Cardiology [Elsevier BV]
卷期号:87 (21): 2996-3012 被引量:2
标识
DOI:10.1016/j.jacc.2026.02.5125
摘要

Background Cardiovascular disease increases risks of chronic kidney disease (CKD) progression and mortality in type 2 diabetes. Objectives The study sought to assess semaglutide effects on kidney and survival outcomes by baseline cardiovascular status in the FLOW trial. Methods Participants with type 2 diabetes and CKD were randomized to once-weekly subcutaneous semaglutide 1.0 mg vs placebo. Baseline subgroups included atherosclerotic cardiovascular disease (ASCVD), heart failure, and high total cardiovascular disease risk without established cardiovascular disease (10-year PREVENT [Predicting Risk of cardiovascular disease EVENTs] score ≥20%). The primary outcome was ≥50% estimated glomerular filtration rate (eGFR) decline, eGFR <15 mL/min/1.73 m , dialysis, transplantation, and kidney or cardiovascular death. All-cause death was a confirmatory secondary outcome. Results At baseline, 1,198 (33.9%) of 3,533, 678 (19.2%) of 3,532, and 1,329 (66.5%) of 2,000 participants had ASCVD, heart failure, or high total cardiovascular disease risk in those without established cardiovascular disease, respectively. Semaglutide reduced the primary outcome risk in subgroups with (119 of 593 vs 146 of 605) or without (212 of 1,174 vs 264 of 1,161) ASCVD (HR: 0.80; 95% CI: 0.63-1.02; and HR: 0.74; 95% CI: 0.62-0.89, respectively; P for interaction = 0.62), with (67 of 342 vs 88 of 336) or without (264 of 1,424 vs 322 of 1,430) heart failure (HR: 0.67; 95% CI: 0.49-0.93; and HR: 0.79; 95% CI: 0.67-0.93, respectively; P for interaction = 0.40), and with (134 of 675 vs 168 of 654) or without (44 of 331 vs 58 of 340) high total cardiovascular disease risk (HR: 0.73; 95% CI: 0.58-0.91; and HR: 0.73; 95% CI: 0.49-1.08, respectively; P for interaction = 0.99). Numbers needed to treat to prevent 1 primary kidney outcome at 3 years were 22, 13, and 17 in the ASCVD, heart failure, and PREVENT score ≥20% subgroups, respectively. Semaglutide also reduced risks of all-cause death with (99 of 593 vs 121 of 605) or without (128 of 1,174 vs 158 of 1,161) ASCVD (HR: 0.82; 95% CI: 0.63-1.07; and HR: 0.78; 95% CI: 0.62-0.99, respectively; P for interaction = 0.79), with (64 of 342 vs 79 of 336) or without (163 of 1,424 vs 200 of 1,430) heart failure (HR: 0.75; 95% CI: 0.54-1.05; and HR: 0.81; 95% CI: 0.66-0.99, respectively; P for interaction = 0.74), and with (73 of 675 vs 98 of 654) or without (23 of 331 vs 28 of 340) high total cardiovascular disease risk (HR: 0.71; 95% CI: 0.52-0.95; and HR: 0.82; 95% CI: 0.47-1.43, respectively; P for interaction = 0.63). Conclusions Semaglutide improved kidney and survival outcomes in type 2 diabetes with CKD, irrespective of established ASCVD, heart failure, or high total cardiovascular disease risk. (Evaluate Renal Function with Semaglutide Once Weekly [FLOW]; NCT03819153 )
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
MZ完成签到,获得积分10
刚刚
小周完成签到 ,获得积分10
刚刚
潜水的土豆完成签到,获得积分10
刚刚
泥泥完成签到 ,获得积分10
刚刚
Cc发布了新的文献求助10
1秒前
1秒前
1秒前
lzz完成签到,获得积分10
1秒前
tony_9_chan完成签到,获得积分10
1秒前
Sissi完成签到,获得积分10
1秒前
冷傲尔安发布了新的文献求助10
1秒前
1秒前
lily完成签到,获得积分10
1秒前
1秒前
downdown完成签到,获得积分10
2秒前
狗蛋完成签到,获得积分10
2秒前
~~~~完成签到,获得积分10
2秒前
初景发布了新的文献求助10
2秒前
汉堡包的应助被传统的松鼠采纳,获得10
2秒前
quhayley完成签到,获得积分0
2秒前
木谦完成签到,获得积分20
4秒前
哎呀马丫完成签到,获得积分10
4秒前
krsL发布了新的文献求助10
4秒前
4秒前
在水一方的应助被小鸡采纳,获得10
5秒前
开朗的语风完成签到 ,获得积分10
5秒前
5秒前
兴奋醉香发布了新的文献求助20
5秒前
5秒前
5秒前
6秒前
呜昂王完成签到,获得积分10
6秒前
6秒前
Sun完成签到 ,获得积分10
6秒前
aa完成签到,获得积分10
6秒前
djt完成签到 ,获得积分10
6秒前
7秒前
lzz发布了新的文献求助10
7秒前
美好乐儿完成签到,获得积分10
7秒前
Nan完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8152442
求助须知:如何正确求助?哪些是违规求助? 9549069
关于积分的说明 21690841
捐赠科研通 7740658
什么是DOI,文献DOI怎么找? 3425157
关于科研通互助平台的介绍 2550382
邀请新用户注册赠送积分活动 2468710